Collapse of the Public Health System and the Emergence of New Variants During the Second Wave of the COVID-19 Pandemic in Brazil

Overview

Journal One Health

Specialty Infectious Diseases

Date 2021 Jul 5

PMID 34222607

Citations 60

Authors

Severino Jefferson Ribeiro da Silva

Lindomar Pena

Affiliations

Soon will be listed here.

Abstract

The worldwide spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the most severe public health crisis since the 1918 Spanish influenza pandemic. After the introduction of public health interventions aimed at reducing the number of COVID-19 cases, many countries across the world obtained success at containing the fast spread of SARS-CoV-2 during the first wave of the pandemic. However, the SARS-CoV-2 has resurged in many countries causing a even more devastating second wave. Brazil is one the most affected countries and currently is facing one of the worst public health crises in its history. Here, we discuss the unprecedented challenges faced by the Brazilian public health system in the midst of the second wave of the COVID-19 pandemic, particularly regarding the collapse of the Brazilian health system and the emergence of new variants of concern (VOCs). Finally, we suggest some insights using a one health approach that will help the country to face and overcome the current COVID-19 crisis.

Citing Articles

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel Strategies.

Barghash R, Gemmati D, Awad A, Elbakry M, Tisato V, Awad K Molecules. 2024; 29(23.

PMID: 39683724 PMC: 11643501. DOI: 10.3390/molecules29235564.

Surge in Mycoplasma Pneumoniae infection and Respiratory Viruses Co-infection in Children With Community-Acquired Pneumonia in the Post-Pandemic.

Chi J, Tang H, Wang F, Wang Y, Chen Z Pediatric Health Med Ther. 2024; 15:279-288.

PMID: 39263589 PMC: 11389692. DOI: 10.2147/PHMT.S473669.

Duration of effectiveness of the COVID-19 vaccine in Japan: a retrospective cohort study using large-scale population-based registry data.

Uemura K, Ono S, Michihata N, Yamana H, Yasunaga H BMC Infect Dis. 2024; 24(1):648.

PMID: 38943060 PMC: 11212202. DOI: 10.1186/s12879-024-09488-6.

Addressing Hospital Overwhelm During the COVID-19 Pandemic by Using a Primary Health Care-Based Integrated Health System: Modeling Study.

Huang J, Qian Y, Yan Y, Liang H, Zhao L JMIR Med Inform. 2024; 12:e54355.

PMID: 38832581 PMC: 11185287. DOI: 10.2196/54355.

Country-report pattern corrections of new cases allow accurate 2-week predictions of COVID-19 evolution with the Gompertz model.

Villanueva I, Conesa D, Catala M, Lopez Cano C, Perramon-Malavez A, Molinuevo D Sci Rep. 2024; 14(1):10775.

PMID: 38730261 PMC: 11087483. DOI: 10.1038/s41598-024-61233-w.

References

Taylor L . Covid-19: Brazil's spiralling crisis is increasingly affecting young people. BMJ. 2021; 373:n879. DOI: 10.1136/bmj.n879. View

Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J . Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021; 592(7854):438-443. DOI: 10.1038/s41586-021-03402-9. View

Zhang W, Davis B, Chen S, Sincuir Martinez J, Plummer J, Vail E . Emergence of a Novel SARS-CoV-2 Variant in Southern California. JAMA. 2021; 325(13):1324-1326. PMC: 7879386. DOI: 10.1001/jama.2021.1612. View

da Silva S, Targino Alves da Silva C, Mendes R, Pena L . Role of nonstructural proteins in the pathogenesis of SARS-CoV-2. J Med Virol. 2020; 92(9):1427-1429. PMC: 7262198. DOI: 10.1002/jmv.25858. View

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(6):803-812. PMC: 7906628. DOI: 10.1016/S1473-3099(20)30987-7. View

Singh J, Rahman S, Ehtesham N, Hira S, Hasnain S . SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021; 27(7):1131-1133. DOI: 10.1038/s41591-021-01397-4. View

Abdool Karim S, de Oliveira T . New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021; 384(19):1866-1868. PMC: 8008749. DOI: 10.1056/NEJMc2100362. View

Dong E, Du H, Gardner L . An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis. 2020; 20(5):533-534. PMC: 7159018. DOI: 10.1016/S1473-3099(20)30120-1. View

Souza W, Amorim M, Sesti-Costa R, Coimbra L, Brunetti N, Toledo-Teixeira D . Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. Lancet Microbe. 2021; 2(10):e527-e535. PMC: 8266272. DOI: 10.1016/S2666-5247(21)00129-4. View

10.

Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M . Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill. 2021; 26(16). PMC: 8063589. DOI: 10.2807/1560-7917.ES.2021.26.16.2100348. View

11.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K . Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2020; 21(2):181-192. PMC: 7832443. DOI: 10.1016/S1473-3099(20)30843-4. View

12.

da Silva S, Mendes R, Targino Alves da Silva C, Lorusso A, Kohl A, Pena L . Insights into SARS-CoV-2, the Coronavirus Underlying COVID-19: Recent Genomic Data and the Development of Reverse Genetics Systems. J Gen Virol. 2020; 101(10):1021-1024. PMC: 7660456. DOI: 10.1099/jgv.0.001458. View

13.

Ranzani O, Bastos L, Gelli J, Marchesi J, Baiao F, Hamacher S . Characterisation of the first 250,000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021; 9(4):407-418. PMC: 7834889. DOI: 10.1016/S2213-2600(20)30560-9. View

14.

Wang P, Nair M, Liu L, Iketani S, Luo Y, Guo Y . Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021; 593(7857):130-135. DOI: 10.1038/s41586-021-03398-2. View

15.

Matthews Q, da Silva S, Norouzi M, Pena L, Pardee K . Adaptive, diverse and de-centralized diagnostics are key to the future of outbreak response. BMC Biol. 2020; 18(1):153. PMC: 7592445. DOI: 10.1186/s12915-020-00891-4. View

16.

Hoffmann M, Arora P, Gross R, Seidel A, Hornich B, Hahn A . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 184(9):2384-2393.e12. PMC: 7980144. DOI: 10.1016/j.cell.2021.03.036. View

17.

Okell L, Verity R, Watson O, Mishra S, Walker P, Whittaker C . Have deaths from COVID-19 in Europe plateaued due to herd immunity?. Lancet. 2020; 395(10241):e110-e111. PMC: 7289569. DOI: 10.1016/S0140-6736(20)31357-X. View

18.

Davies N, Abbott S, Barnard R, Jarvis C, Kucharski A, Munday J . Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538). PMC: 8128288. DOI: 10.1126/science.abg3055. View

19.

Wang P, Casner R, Nair M, Wang M, Yu J, Cerutti G . Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021; 29(5):747-751.e4. PMC: 8053237. DOI: 10.1016/j.chom.2021.04.007. View

20.

Faria N, Mellan T, Whittaker C, Claro I, Candido D, Mishra S . Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021; 372(6544):815-821. PMC: 8139423. DOI: 10.1126/science.abh2644. View